Core Viewpoint - The company reported a decline in revenue and net profit for 2025, while focusing on product iteration and the construction of a "device + IT + AI" smart medical ecosystem [2][3][25]. Performance Summary - In 2025, the company achieved operating revenue of 33.282 billion yuan, a year-on-year decrease of 9.38% - The net profit attributable to shareholders was 8.136 billion yuan, down 30.28% year-on-year [3]. - The non-recurring net profit was 8.069 billion yuan, a decline of 29.48% year-on-year - Operating cash flow was 10.145 billion yuan, down 18.40% year-on-year - The weighted ROE was 21.58%, a decrease of 11 percentage points - Total assets reached 59.267 billion yuan, an increase of 4.63% year-on-year - Net assets attributable to shareholders were 38.093 billion yuan, up 6.24% year-on-year [5]. Revenue Structure - International business revenue was 17.650 billion yuan, an increase of 7.40% year-on-year, accounting for 53% of total revenue - Domestic business revenue was 15.632 billion yuan, a decrease of 22.97% year-on-year [5]. Product and Technology - The company is advancing product upgrades in the in vitro diagnostics (IVD) sector, focusing on full laboratory solutions [7]. - The MT 8000 full laboratory intelligent assembly line was installed in over 20 overseas locations and received more than 360 new orders domestically [8]. - The company introduced 14 new immunoassay reagents, bringing the total to 94, with some achieving "mass spectrometry level" performance [10]. - The company is developing a monitoring and anesthesia integration system for surgical and ICU scenarios [11]. - The Resona A20 high-end ultrasound system is designed for tumor and complex disease imaging, featuring microvascular perfusion imaging capabilities [14]. R&D, Business, and Market - The company continues to invest in R&D, global expansion, and the construction of a smart medical ecosystem [21]. - Over 21,000 employees globally, with more than 24% in R&D roles, and multiple R&D centers established worldwide [23]. - The IVD business accounts for approximately 48% of domestic revenue, with emerging businesses and IVD combined accounting for nearly 70% [23]. - The European market grew by 17% year-on-year, with international emerging business growth nearing 30% [23]. Future Outlook - The company aims to maintain revenue above 30 billion yuan in 2025, with an increasing share of international business [25]. - Continuous product upgrades in IVD assembly lines, high-end imaging, and multi-scenario device integration are prioritized [25][26].

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics industry [4][54]. Core Views - The in vitro diagnostics industry is stabilizing due to policy and technological advancements, including the accelerated integration of AI in diagnostics, the implementation of price reforms, and the stabilization of centralized procurement impacts [4][54]. - The report highlights the importance of focusing on specific growth areas within the industry, such as chemiluminescence in immunodiagnostics and PCR in molecular diagnostics, with companies like YHLO and Shengxiang Bio being recommended for attention [4][54]. Summary by Sections Industry Performance - The pharmaceutical and biological sector decreased by 0.39%, while the in vitro diagnostics sector increased by 0.42% during the week [1][20]. - The in vitro diagnostics sector's PE ratio is currently at 40.90X, with a recent increase of 0.17X, and the PB ratio is at 1.87X, up by 0.01X from the previous week [3][30]. Key Developments - AI diagnostics are evolving from auxiliary tools to core components of clinical processes, enhancing diagnostic efficiency and driving industry modernization [4][54]. - The Chongqing Medical Insurance Bureau has introduced a price reform draft for pathological services, which is expected to enhance the value recognition of diagnostic services [4][54]. - The impact of centralized procurement is stabilizing, with price pressures gradually easing and testing volumes expected to stabilize following the unbundling of service packages [4][54]. Company Performance - Notable companies in the medical services sector include Aotai Bio (+7.9%), Saikexide (+4.5%), and Mingde Bio (+4.0%), while underperformers include Rejing Bio (-8.7%) and Botuo Bio (-3.3%) [2][25]. - The report suggests that the domestic biochemical diagnostics sector has largely overcome foreign constraints, indicating a completed localization process [4][54].

Core Viewpoint - The medical device sector is experiencing slight fluctuations, with the medical device ETF reaching a historical high of 3.22 billion yuan, despite a minor decline of 0.11% [1] Industry Overview - The global IVD (in vitro diagnostics) market is maintaining steady growth, while the domestic market faces some pressure due to DRG/DIP policies. However, the demand for medical testing remains robust due to aging demographics [1] - The domestic biochemical diagnostics sector has largely overcome foreign dependencies, with the localization process nearly complete [1] Company Developments - The "Qiyuan Inspection Model," the first vertical large model focused on clinical testing in China, was officially launched at the Southern Inspection Medicine Academic Conference. This model was developed collaboratively by Mindray Medical and Southern Medical University Shenzhen Hospital, with support from multiple departments in Shenzhen [1] - The "Qiyuan" model differentiates itself from general large models by systematically building the reasoning and thinking capabilities of medical experts through a four-step process: professional learning, clinical training, thinking simulation, and continuous evolution [1] Market Performance - As of 14:24 on November 26, the medical device ETF (562600) showed a slight decline of 0.11%, with leading stocks including Haorunbo, Weili Medical, Lexin Medical, Dian Diagnostics, and Shuoshi Biology showing strong upward trends [1]

Core Viewpoint - The launch of the "QiYuan Inspection Model" marks a significant advancement in China's clinical inspection field, showcasing the integration of artificial intelligence in medical diagnostics and addressing the core challenges of clinical inspection automation and intelligent decision-making [2][4]. Industry Overview - Clinical inspection is a crucial support for modern medical systems, influencing over 70% of clinical decision-making. Traditional inspection processes face challenges such as large information volumes, complex workflows, and heavy manual review burdens. The explosive growth of medical data has led to high expectations for AI to assist in automatic analysis and intelligent decision-making [4]. - The limitations of general-purpose large language models (LLMs) in the medical field stem from their broad but non-specialized nature, which often fails to provide precise conclusions in complex experimental data and professional judgment tasks. The focus has shifted to developing vertical models that can truly understand inspection logic and possess expert thinking [4]. - In August 2025, the State Council issued opinions to promote the deep integration of AI with key areas such as healthcare, encouraging the development of specialized AI models in the medical field [4]. Company and Technology Background - Mindray Medical, a leading global provider of medical devices and solutions, has been intensifying its AI research and development efforts, forming a technology matrix centered on "AI + medical imaging," "AI + monitoring," and "AI + inspection" [6]. - Since 2023, Mindray has been advancing the "QiYuan" medical model system, with the core achievement being the QiYuan Critical Care Model, which focuses on clinical decision support in ICU settings and has been implemented in several large hospitals [8]. Product Introduction - The "QiYuan Inspection Model" distinguishes itself from general AI through its specialization and interpretability, following a four-stage training system: professional learning, clinical training, thinking simulation, and continuous evolution [9][10]. - The model has been applied in hospitals, significantly reducing the time required for complex report reviews from 20-30 minutes to just 1 minute [11]. - It features automated risk identification and suggestions for retesting when anomalies are detected, creating an automated feedback loop from anomaly detection to correction [12]. - The model integrates multi-source data for comprehensive analysis, enhancing the basis for clinical judgment [13]. - It also supports clinical communication by automatically generating suggestions for follow-up tests and potential interference factors, improving collaboration between inspection and clinical departments [14]. Open Ecosystem and Future Expansion - Mindray plans to open the "QiYuan Inspection Model" to more medical institutions for collaborative optimization and adaptation to specific diseases, establishing a sustainable evolving medical intelligence platform [15]. Conclusion - The release of the "QiYuan Inspection Model" represents a milestone in China's inspection medicine, signifying a shift from passive reporting to active decision-making participation [16]. - The model is expected to significantly enhance inspection efficiency and report accuracy, allowing doctors to focus on high-value clinical judgments and research innovation [17]. - Mindray's "QiYuan" model system is building the foundation for China's medical AI industry, creating a closed loop of data, models, and applications that will support the standardization and internationalization of intelligent healthcare in the future [17].